Dihydrotestosterone pathway (None (the pathway itself is not commonly abbreviated; DHT is the abbreviation for dihydrotestosterone, a key molecule in the pathway))

The dihydrotestosterone pathway, also known as androgen metabolism leading to dihydrotestosterone synthesis, encompasses all biochemical reactions responsible for converting testosterone into dihydrotestosterone (DHT) primarily through the action of 5α-reductase enzymes, especially types I and II. This conversion occurs mainly in tissues such as prostate gland, skin/hair follicles, liver, brain, and genitalia. The resulting hormone (DHT) binds with high affinity to the androgen receptor—more potently than testosterone—and mediates critical biological processes including male sexual differentiation during embryogenesis/fetal life; maturation at puberty; growth/maintenance of prostate gland; sebum production; body/facial/pubic hair growth; and regulation/loss of scalp hair. Dysregulation or overactivity within this metabolic route underlies several clinical conditions including benign prostatic hyperplasia (BPH), male pattern baldness (androgenetic alopecia), certain forms of congenital adrenal hyperplasia (CAH), virilization syndromes in females/newborns due to alternate ("backdoor") pathways, polycystic ovary syndrome (PCOS) in women, among others. Pharmacologic intervention most commonly targets either inhibition of 5α-reductase enzymes, thereby reducing tissue/local/systemic concentrations of active DHT (finasteride, dutasteride), or antagonism/modulation at downstream androgen receptors. In summary: “Dihydrotestosterone pathway” refers broadly to all enzymatic steps producing active DHT from precursors like testosterone/progesterone via classic/alternate routes—not a single molecular entity suitable as canonical drug target.

Other names

DHT biosynthesisAndrogen metabolismTestosterone 5α-reduction

Inhibition of testosterone conversion to dihydrotestosterone via blockade of 5α-reductase enzyme activity, reducing local/tissue DHT levels. Antagonism/blockade of androgen receptor activation by DHT.